The 10-second takeaway
Comparing the upcoming quarter to the prior-year quarter, average analyst estimates predict Insulet's revenues will increase 20.0% and EPS will remain in the red.
The average estimate for revenue is $57.3 million. On the bottom line, the average EPS estimate is -$0.21.
Last quarter, Insulet tallied revenue of $57.8 million. GAAP reported sales were 23% higher than the prior-year quarter's $47.2 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Last quarter, EPS came in at -$0.21. GAAP EPS were -$0.21 for Q4 against -$0.30 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the preceding quarter, gross margin was 43.8%, 130 basis points better than the prior-year quarter. Operating margin was -10.5%, 820 basis points better than the prior-year quarter. Net margin was -17.6%, much better than the prior-year quarter.
The full year's average estimate for revenue is $248.4 million. The average EPS estimate is -$0.59.
The stock has a one-star rating (out of five) at Motley Fool CAPS, with 67 members out of 108 rating the stock outperform, and 41 members rating it underperform. Among 37 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 24 give Insulet a green thumbs-up, and 13 give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Insulet is outperform, with an average price target of $24.24.
Is Insulet the best health care stock for you? Learn how to maximize your investment income and "Secure Your Future With 9 Rock-Solid Dividend Stocks," including one above-average health care logistics company. Click here for instant access to this free report.
- Add Insulet to My Watchlist.